BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 1532766)

  • 1. Quantitation of folic acid enhancement of antifolate synergism.
    Gaumont Y; Kisliuk RL; Parsons JC; Greco WR
    Cancer Res; 1992 Apr; 52(8):2228-35. PubMed ID: 1532766
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antifolate drug interactions: enhancement of growth inhibition due to the antipurine 5,10-dideazatetrahydrofolic acid by the lipophilic dihydrofolate reductase inhibitors metoprine and trimetrexate.
    Galivan J; Nimec Z; Rhee M; Boschelli D; Oronsky AL; Kerwar SS
    Cancer Res; 1988 May; 48(9):2421-5. PubMed ID: 2965613
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synergistic growth inhibition of rat hepatoma cells exposed in vitro to N10-propargyl-5,8-dideazafolate with methotrexate or the lipophilic antifolates trimetrexate or metoprine.
    Galivan J; Nimec Z; Rhee M
    Cancer Res; 1987 Oct; 47(20):5256-60. PubMed ID: 2958130
    [TBL] [Abstract][Full Text] [Related]  

  • 4. N10-propargyl-5,8-dideazafolic acid (CB3717): inhibitory effects on human leukemia cell lines resistant to methotrexate or trimetrexate.
    Takemura Y; Ohnuma T
    Mt Sinai J Med; 1992 Oct; 59(5):419-24. PubMed ID: 1435841
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Folic acid-enhanced synergy for the combination of trimetrexate plus the glycinamide ribonucleotide formyltransferase inhibitor 4-[2-(2-amino-4-oxo-4,6,7,8-tetrahydro-3H-pyrimidino[5,4,6][1,4]thiazin -6-yl)-(S)-ethyl]-2,5-thienoylamino-L-glutamic acid (AG2034): comparison across sensitive and resistant human tumor cell lines.
    Faessel HM; Slocum HK; Rustum YM; Greco WR
    Biochem Pharmacol; 1999 Mar; 57(5):567-77. PubMed ID: 9952321
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The enhancement of the activity of 10-propargyl-5,8-dideazafolate and 5,10-dideazatetrahydrofolate by inhibitors of dihydrofolate reductase.
    Galivan J; Rhee MS; Johnson TB; Chou TC; Nair MG; Bunni M; Priest D
    Adv Enzyme Regul; 1989; 28():13-21. PubMed ID: 2624172
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of combined antifolates on inhibition of growth of murine leukemia cells cultured in vitro.
    Balińska M; Szablewska I; Janiszewska D; Bartuzi K; Pawełczak K
    Acta Biochim Pol; 1997; 44(4):743-50. PubMed ID: 9584854
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytotoxicity of antifolate inhibitors of thymidylate and purine synthesis to WiDr colonic carcinoma cells.
    Smith SG; Lehman NL; Moran RG
    Cancer Res; 1993 Dec; 53(23):5697-706. PubMed ID: 8242626
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biochemical studies on PT523, a potent nonpolyglutamatable antifolate, in cultured cells.
    Rhee MS; Galivan J; Wright JE; Rosowsky A
    Mol Pharmacol; 1994 Apr; 45(4):783-91. PubMed ID: 7514264
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparison of the effects of nine folate analogs on early and late murine hematopoietic progenitor cells in vitro.
    Strømhaug A; Warren DJ
    Cancer Chemother Pharmacol; 2000; 45(6):450-6. PubMed ID: 10854131
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Super in vitro synergy between inhibitors of dihydrofolate reductase and inhibitors of other folate-requiring enzymes: the critical role of polyglutamylation.
    Faessel HM; Slocum HK; Jackson RC; Boritzki TJ; Rustum YM; Nair MG; Greco WR
    Cancer Res; 1998 Jul; 58(14):3036-50. PubMed ID: 9679969
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Carrier- and receptor-mediated transport of folate antagonists targeting folate-dependent enzymes: correlates of molecular-structure and biological activity.
    Westerhof GR; Schornagel JH; Kathmann I; Jackman AL; Rosowsky A; Forsch RA; Hynes JB; Boyle FT; Peters GJ; Pinedo HM
    Mol Pharmacol; 1995 Sep; 48(3):459-71. PubMed ID: 7565626
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thymidine and hypoxanthine protection patterns of the folic acid-enhanced synergies for combinations of trimetrexate plus a polyglutamylatable inhibitor of purine or thymidylate synthesis against human ileocecal HCT-8 cells.
    Faessel HM; Slocum HK; Rustum YM; Greco WR
    Int J Oncol; 2003 Aug; 23(2):401-9. PubMed ID: 12851689
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanism of cell death following thymidylate synthase inhibition: 2'-deoxyuridine-5'-triphosphate accumulation, DNA damage, and growth inhibition following exposure to CB3717 and dipyridamole.
    Curtin NJ; Harris AL; Aherne GW
    Cancer Res; 1991 May; 51(9):2346-52. PubMed ID: 2015598
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of cellular folates in the enhancement of activity of the thymidylate synthase inhibitor 10-propargyl-5,8-dideazafolate against hepatoma cells in vitro by inhibitors of dihydrofolate reductase.
    Galivan J; Rhee MS; Johnson TB; Dilwith R; Nair MG; Bunni M; Priest DG
    J Biol Chem; 1989 Jun; 264(18):10685-92. PubMed ID: 2525127
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activity of the thymidylate synthase inhibitor 2-desamino-N10-propargyl-5,8-dideazafolic acid and related compounds in murine (L1210) and human (W1L2) systems in vitro and in L1210 in vivo.
    Jackman AL; Taylor GA; O'Connor BM; Bishop JA; Moran RG; Calvert AH
    Cancer Res; 1990 Sep; 50(17):5212-8. PubMed ID: 2386929
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Functional activity of the reduced folate carrier in KB, MA104, and IGROV-I cells expressing folate-binding protein.
    Westerhof GR; Rijnboutt S; Schornagel JH; Pinedo HM; Peters GJ; Jansen G
    Cancer Res; 1995 Sep; 55(17):3795-802. PubMed ID: 7641196
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of glycinamide ribonucleotide formyltransferase and other folate enzymes by homofolate polyglutamates in human lymphoma and murine leukemia cell extracts.
    Thorndike J; Gaumont Y; Kisliuk RL; Sirotnak FM; Murthy BR; Nair MG; Piper JR
    Cancer Res; 1989 Jan; 49(1):158-63. PubMed ID: 2521177
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multifactorial resistance to 5,10-dideazatetrahydrofolic acid in cell lines derived from human lymphoblastic leukemia CCRF-CEM.
    Pizzorno G; Moroson BA; Cashmore AR; Russello O; Mayer JR; Galivan J; Bunni MA; Priest DG; Beardsley GP
    Cancer Res; 1995 Feb; 55(3):566-73. PubMed ID: 7834626
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tight binding of folate substrates and inhibitors to recombinant mouse glycinamide ribonucleotide formyltransferase.
    Sanghani SP; Moran RG
    Biochemistry; 1997 Aug; 36(34):10506-16. PubMed ID: 9265631
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.